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An overwhelming  body of evidence exists showing that the antibody mole- 
cules formed in response to a  single well defined antigen are not homogeneous, 
but differ from one another in many physical and chemical properties  (1).  In 
addition,  even among antibodies  of the same molecular size made in response 
to a  single antigen, there is considerable evidence of heterogeneity of such anti- 
body by chemical, physical, immunochemical, and biological tests  (1). 
Previous work from this laboratory  (2,  3)  and by Maurer  (4)  has  demonstrated 
that  dextrans  are  antigenic  in man.  Following the  injection  of a  dextran  which is 
predominantly  a-l,6-1inked,  the  specificity  of  the  antidextran  formed  is  directed 
towards  sequences  of  terminal  non-reducing  a-l,6-1inked  glucose  units.  This  has 
been  shown by the  quantitative  hapten  inhibition  technique  with  the  homologous 
series  of ~-l,6-1inked  glucose  oligosaccharides  (isomaltose  series).  In  this  system, 
the  oligosaceharide which has  the  greatest  capacity  to inhibit  dextran-antidextran 
precipitation on a molar basis presumably by fitting best into the antibody-combining 
site, is inferred to have a  structure most similar to the antigenic determinant on the 
dextran. With various antidextran sera of 1,6 specificity, maximum inhibiting power 
on a  molar basis was obtained with isomaltohexaose and isomaltoheptaose,  the two 
oligosaccharides being equal in inhibiting power with six antisera; with antidextran 
from a  seventh  individual  the  heptasaccharide  was  slightly better  as  an  inhibitor. 
Thus, the upper limit in the size  of the antibody combining site has been shown to 
be in the range of a  hexa- to a heptasaccharide  (5, 6). 
Antidextran produced in a  single  individual has been thought to consist of a  het- 
erogeneous  population  of  antibody  molecules  with  antibody-combining  sites  of 
different sizes,  varying from an undetermined lower limit to sites complementary to 
a  hexa- or heptasaccharide.  This  is  inferred  from the  observation that under corn- 
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parable assay conditions the ratio of inhibiting power of the various oligosaccharides 
to one another  varied with  antidextrans  obtained from different individuals  (6). 
The experiments reported in this study provide further support for this hy- 
pothesis  since it was possible  to fractionate  the antidextran  from the sera of 
each of two individuals into two populations of antibody molecules and to show 
that these populations differed from each other and from the antibody in the 
original serum in the ratios of inhibiting power of the various oligosaccharides 
to one another and hence in the proportions of molecules with combining sites 
of various sizes. The two purified antibody fractions showed the same behavior 
in immunoelectrophoresis  indicating  that  the  fractionation  had  not been ac- 
complished on the  basis  of differences  in physicochemical properties.  Differ- 
ences between the two antibody fractions were found in quantitative precipitin 
studies  with dextrans  of varying molecular weight  (7).  In addition,  oligosac- 
charide inhibition assays carried out with whole serum differed from those with 
purified  antibody  in  that  substantially  less  of  a  given  oligosaccharide  was 
needed to inhibit precipitation in whole serum than was required with purified 
antibody alone; this decrease in the quantity of oligosaccharide needed for in- 
hibition  could  be  achieved  by adding  albumin,  gamma  globulin  fraction  II, 
or polyvinylpyrrolidone. Its basis is not understood. It was also observed that 
over a  10 year period,  the population of antidextran-combining  sites  in both 
individuals,  as established from inhibition data, showed only minimal changes. 
The  method  of purification  of  the  antidextran  and  the  fractionation  into 
the two populations involved absorption of the antibody on an insoluble dex- 
tran  (sephadex),  washing  to remove  non-specific protein  and  elution  in  two 
steps,  first with a  small oligosaccharide such as isomaltose (IM2) or isomalto- 
triose  (IM3)  to remove antibodies  with higher  affinities  for smaller  oligosac- 
charides,  followed by elution of the remaining antibody with isomaltohexaose 
(IM6). 
Materials and Methods 
Oligosaccharides.--The isomaltose  series of oligosaccharides  from  isomaltose  (IM2)  to 
isomaltoheptaose  (IM7)  was prepared  as described by Turvey and Whelan  (8) with some 
modifications. 30 gm of a clinical dextran,  intradex  batch 54/156 May, 1954, manufactured 
by the Glaxo Laboratories  Ltd.,  Greenford, England,  was  hydrolyzed in 0.33 N I-I,  SO, at 
100°C for 4 hours, neutralized,  and dialyzed. The dialyzable oligosaccharides were concen- 
trated,  made up in 1 per cent aqueous ethanol and placed on a column containing 200 gm 
darco-100 gm celite. The column was washed copiously with  1 per cent ethanol until  very 
mall amounts  of reducing sugar appeared  in the eflfluent. The oligosaccharides were then 
eluted successively with 5, 7.5, 10, 12.5, and 15 per cent ethanol. Fractions of 1.5 to 2.0 liters 
were collected and those containing chiefly a single oligosaccharide were pooled and concen- 
trated.  Further purification of each oligosaccharide was accomplished by preparative  paper 
chromatography  on Whatman  17 using propanol:ethyl acetate:water  (6:1:3).  Individual 
spots were located by guide strips cut from each paper, the regions corresponding to a given 
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in ~acuo, dissolved in 20 per cent alcohol, a  small amount of darco added, and the mixture 
filtered through a  bed of celite on an ultrafine sintered glass filter. The filtrate was concen- 
trated,  taken up in absolute ethanol and dried. Isomaltose and isomaltotriose were rechro- 
matographed on a 50 gm darco-25 gm celite column eluted with a continuous ethanol gradient, 
the regions of the peaks being concentrated and taken up in absolute ethanol and dried. Each 
oligosaccharide gave a  single spot  on paper  chromatography  corresponding to that  of the 
known  compounds.  Samples of isomaltose and  isomaltotriose were supplied by Dr.  Allene 
Jeanes and the tetra-, penta-, hexa- and heptasaccharides were furnished by Dr. W. J. Whelan, 
Dr. J. R. Turvey, and Dr. S. Haq. The isolated compounds from the di- to the heptasaccharide 
had [cz]  D values of +111 °, +137 °, +141 °, +151 °, -{-158  °, and +164  °, respectively, calculated 
on a  weight basis.  The previously reported values calculated on the basis of sugar content 
were slightly higher (8). 
Dextra~.--Clinical dextran N  150 N and the series of National Research Council dextran 
fractions of graded molecular weight, prepared from the B  512 strain of Leuconostoe mesen- 
tero/de.y., were those used in earlier studies  (7, 9). The weight-average molecular weights of 
NRC fractions 1, 2, 3, 6, and 7 were 10,600, 35,000, 51,300, 194,900, and 255,000, respectively. 
Sephadex  G-75,  medium grade,  an insoluble dextran  used for gel filtration studies  was 
purchased from Pharmacia, Uppsala, Sweden. 
Antidextmn.--Antidextran  sere from two individuals, 1 and 20, were available; quantita- 
tive precipitin and inhibition curves on earlier bleedings as well as data on antibody levels 
over a long period have been published  (3, 6, 5,  10). Serum sample 20Ds from which inhibi- 
tion curves had previously been derived and published was also used for the antibody purifica- 
tion studies. In addition, serum samples 1D24-2s and 20Dlt were obtained 10 years after the 
initial immunization, which had consisted of two injections each of 0.5 mg dextran,  1 day 
apart.  All antisera were preserved with 0.25 per cent phenol and  1:10,000  merthiolate and 
were stored in the refrigerator. A sample of antidextran from  subject 20Dg purified by  di- 
gestion of the dextran-antidextran specific precipitate with dextranase as described in reference 
11  (cf. reference 1) was available. It had been prepared in September, 1956, from a sample of 
blood  drawn  in  September,  1954. 
Other Sera.--Horse antiserum to human serum (223-224)  (Serpasteur,  Paris)  was kindly 
supplied  by Dr. Pierre  Grabar.  Sheep anti-~sA-myeloma globulin antiserum  was furnished 
by Drs. Howard Goodman and Arthur Strauss of the National Institutes of Health. Rabbit 
anti-'y-globulin  (pool  59)  was  prepared  as  described  in  earlier publications  (12).  Rabbit 
antiserum to A-anti-A specific precipitates,  1342.s, was the same as reported in (13).  Serum 
B1, from a  patient with lupus erythematosus was kindly supplied by Dr. C. L. Christian. 
Quantitative  Precipitin  and  Inhibition  Studies.--Quantitative  precipitin curves were ob- 
tained using whole antiserum, purified antibody solutions, or purified antibody solutions to 
which normal human serum or the superuatant from a sephadex-absorbed antidextran serum 
had  been added  to provide a  high protein concentration. 
The quantitative precipitin assays were set up by adding a volume of antiserum or anti- 
body solution containing in various experiments 2.6 to 5.7/zg Ab N to a series of 3 ml conical 
centrifuge tubes to which known quantities of dextran had been added, the tubes made up 
to a given volume and their contents mixed (cf. reference 1). After 1 hour at 370 and 1 week 
in the refrigerator, during which the contents of the tubes were mixed twice a day, the tubes 
were centrifuged in a refrigerated centrifuge and the precipitates were washed with a volume 
of chilled saline equal to the total volume in which the original assay had been made, generally 
0.3 ml. Two washings were used for determinations in whole serum and one with those using 
purified antibody solutions. The precipitates were digested with sulfuric acid and the total N 
measured by the ninhydrin method recently described (14, 15). 
Inhibition assays were carried out in the usual manner on the micro scale (el.  1) using 3 
ml centrifuge tubes and about  3.5 #g Ab N  per analysis. Known concentrations of oligosac- 538  SPECIFIC  FRACTIONATION  OF  ANTIDEXTRAN  ~fOLECULES 
charide and antibody were mixed, incubated 30 minutes at 37  ° C, dextran added, the con- 
tents of the tubes again mixed, incubated 1 hour at 37  °, placed in the refrigerator for 1 week 
and the washing and analyses carried out as above. Inhibition assays were carried out with 
whole  antiserum, purified  antibody,  or with purified  antibody to  which normal serum or 
sephadex-absorbed  antidextran  serum  had  been  added.  In  some  instances  polyvinylpyr- 
rolidone, albumin, or normal gamma globulin Fr. II (Lederle lot C 685) were used instead of 
normal serum. 
It was found in some instances that the addition of normal serum to a  given amount of 
purified antibody affected somewhat the ability of this antibody to be precipitated by the 
same amount of dextran N  150 N. Thus with both the 20D3-IM3Ab and 20Da-IM6Ab only 
2.8 #g Ab N  was precipitated by 1.7 #g N  150 N in serum, although 4.0 and 3.35 #g Ab N 
of these purified antibodies were present, respectively. With the 1D2~_25-IM2Ab  and 1D24-25- 
IM6Ab no effect of serum was observed as 3.45 and 3.5 #g Ab N  were precipitated by 1.7 
#g N  150 N in serum to which 3.44 and 3.72 #g Ab N  had been added. A  reduction in the 
amount of antibody N precipitated in the presence of normal gamma globulin, albumin, and 
polyvinylpyrrolidone was found. 
Immunoelectrophoresis.--A modification of the method of Grabar and Williams (of. reference 
16) was employed using 50 X  75 mm glass slides coated with 0.1 per cent ionagar 2  (Con- 
solidated Labs., Inc., Chicago) and covered with 6.5 ml buffered (0.1  ~  barbital-HC1 buffer 
pH 8.2) 1.5 per cent ionagar. The electropboresis was run in the same buffer for approximately 
3 hours, and the voltage adjusted between 100-140v to maintain 6 ma  per slide.  Wells and 
troughs were cut with an agar cutter  (Buchler Instruments, Inc.,  Fort Lee,  New  Jersey) 
and after addition of antiserum to the troughs, the slides were kept from 24 to 48 hours in 
the refrigerator for reactions to develop. 
Afar Diffuaion.--Double  diffusion in agar was carried out  according to  the method of 
Ouchterlony (17,  18)  with minor modifications.  1 per cent agar dissolved in 0.5 ~t glycine 
(19) was poured onto a 25 X  75 mm glass slide to a thickness of about 2 mm and after hard- 
ening, wells were cut with a 3 mm cork borer. The slides were allowed to develop in the re- 
frigerator for 24 to 48 hours after addition of antigens and antibody. 
Pur,'fwation and Fractionation of Antidextran.--The  principle of the method involves the 
specific absorption of the antidextran on an insoluble dextran (sephadex G-75), removal of 
non-specific protein by washing and fractional extraction of part of the antibody with iso- 
maltose  (IM2)  or isomaltotriose  (IM3), followed by extraction of the remaining antibody 
with IM6.  The recovered antibody solutions were  freed  from  oligosaccharide by dialysis. 
The specific procedure was as follows:--120 mg washed, packed sephadex G-75 medium 
grade was suspended in  125 ml antidextran 1D24.25  containing a  total of  1.25  mg Ab N. 
Mter 1 hour at 37°C with frequent mixing, the tube was placed in the refrigerator on a clock 
motor rotating at 6 Rp~x and allowed to rotate for 1 week. A  quantitative precipitin test on 
the supematant showed complete removal of antidextran, and further evidence of specificity 
was demonstrated by showing that no antilevan which was also present in the 1D~4-25 anti- 
serum had been removed by sephadex. The sephadex specific precipitate was centrifuged and 
washed repeatedly in the cold with saline until no significant amount of material absorbing 
at 2800 A could be detected in the washings. It was resuspended in 2 ml of solution containing 
a total of 50 mg of isomaltose, incubated at 37°C for one hour, and placed in the refrigerator 
overnight. The sephadex was  centrifuged off,  the supernatant containing the antidextran 
extractable by isomaltose was removed, the sephadex was given several small washings with 
cold saline, and these were  combined with the main isomaltose extract  (1D24-25-IM2Ab). 
The sephadex was then extracted with 2 ml of saline containing a total of 40 mg of isomalto- 
hexaose, kept at 37  ° for 1 hour and in the refrigerator overnight, centrifuged, and the super- 
natant removed. A  second extraction was carried out with 60 mg of isomaltohexaose in  1 
ml of cold saline and after several hours in the cold, the sephadex was centrifuged, the super- STUART  ~.  SCHLOSSMAN  AND  ELVIN  A.  KABAT  539 
natant removed and saved, and the sephadex was then given several further washings with 
saline  which were  added  to  the  isomaltohexaose extracts  (1Dz~_25-IM6Ab).  The  IM2Ab 
and IM6Ab extracts were dialyzed with constant stirring in the cold against buffered saline 
(st/1000 sodium phosphate pH 7.3)  to which a  drop of toluene had been added. The saiine- 
phosphate was replaced daily until the dialysate was free of reducing sugar as assayed by the 
Park-Johnson method  (of.  reference 1).  A  small amount of insoluble material appeared on 
dialysis, which was centrifuged off, yielding the purified antibody solutions. 
The same procedure was followed with 80 ml 20D3 containing a  total of 3.57 mg anti- 
dextran N  except that 340 mg sephadex was used to remove the antibody; the first extraction 
TABLE  I 
Analytical  Properties  of Purified  Antidextran  Solutions 
Antidextran used 
1 D24-25 
1.25 rag. 
Ab N 
20D~ 
3.57 mg. 
Ab N 
Antibody ehted with isomaltose 
Ab N 
precipi-  Ab N 
Total N  table by  Total N 
i N 150 N* 
ttg  ttg  per cent 
296  221  75 
Antibody duted by isomaltotriose 
1890  1330  70  37 
Antibody eluted by isomaltohexaose 
Ab N 
Total N 
pet ¢~t4 
58 
79 
Ab N 
precipi- 
Yield  Total N  table by 
N  150 N* 
per cent  ~g  I~g 
18  413  240 
1120  880 
Yield 
per cent 
19 
25 
Total 
yield of 
antibody 
per cent 
37 
62 
* The values reported  are those actually obtained on analysis.  Since on the microscale 
employed,  blank values on adding antibody to saline in control tubes ranged from 0.4 to 
1 pg N, which has been shown to be due to non-specific adsorption of protein by glass, values 
could be lower by this amount per analysis. When corrected for this, the total amount of 
antidextran N  recovered would be 236 #g by IM2 and 267 pg by IM6 for antiserum 1, and 
1560 #g by IM3, and 970/zg by Ig6  for antiserum 20,--increasing somewhat the values for 
Ab N/total N; e.g., the purity of the recovered antibody as well as the yields. 
of the antibody was with 152 mg isomaltotriose (20D3-IM3Ab) and the second with 150 mg 
isomaltohexaose (20Dz-IM6Ab). 
RESULTS 
Table I  summarizes  the analytical data on the purified antibody solutions. 
The data show fractionation of the total antibody into two fractions with each 
antiserum, one  extractable with the smaller  oligosaccharide  and  the second 
with the isomaltohexaose. Over-all yields of antibody were 37 and 62 per cent 
and the two fractions were of comparable purity. 
Inhibition Studies with the Purified Antibody Fractions.--The behavior of the 
purified antibody fractions in quantitative inhibition tests using the isomaltose 
series of oligosaccharides is given in Text-figs.  1 and 2A and 2B. With both 
antisera it is evident that IM2Ab or IM3Ab differed markedly from the IM6Ab. ® 
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Thus from antiserum  1D~.~  (Text-fig. 1),  the IM2Ab was readily inhibited 
by IM2 and IM3, while the IM6Ab was only poorly inhibited by IM2. From 
antiserum 20Da  (Text-figs. 2A and 2B), the IM3Ab was inhibitable by IM2 
and IM3 while the IM6Ab was not inhibited significantly with either of these 
oligosaccharides within the range studied. With each antibody fraction, how- 
ever, somewhat better inhibition was obtained with higher oligosaccharides. 
Thus, with both the 1D~_~5-IM2Ab and the 1D24.~5-IM6Ab, IM6 was some- 
what better as an inhibitor than IM5, which was better than IM4; it is apparent 
that in the IM6Ab the spread in inhibiting power between IM4 and IM6 was 
obviously less  than for the IM2Ab at the 50 per cent point; the differences 
between IM3 and IM6 for the two antibody fractions are more striking. 
With antiserum 20D3 in which much more antibody was available for analy- 
sis, the differences between the IM3Ab and the IM6Ab are even more striking. 
With  the  IM3Ab,  IM2  and  IM3  gave substantial  inhibition  (Text-fig.  2A) 
while with the IM6Ab, these two oligosaccharides did not inhibit at all in the 
range tested  (Text-fig. 2B).  In  the IM3Ab,  IM4 was  better as an inhibitor 
than IM3 and IM5 was better than IM4. However, IMS, IM6, and IM7 were 
all equally potent on a molar basis. On the other hand with the IM6Ab, IM7 
was definitely superior as an inhibitor to IM6 and the inhibiting power of the 
others decreased with decreasing chain length. 
Inhibition Studies on the Purified Antibody Fractions in a High Protein Me- 
dium.--The inhibition studies with purified antibody revealed that it was more 
difficult to inhibit precipitation than had been found with the same amount 
of antibody in unfractionated serum (see Text-fig. 4). It was therefore of im- 
portance to determine whether this resulted from the fraetionation procedure 
or was related to the medium in which the inhibition was carried out. Quanti- 
tative inhibition tests were set up using the same amount of purified antibody 
fractions and oligosaccharide inhibitors in the presence of sephadex-absorbed 
20D3 serum or of normal human serum to provide a high protein concentration. 
In Text-fig. 1, the points with asterisks were obtained in the presence of normal 
serum, and it is apparent that both the IM3Ab and the IM6Ab are more readily 
inhibited in the presence of serum. With the 20Ds-IM3Ab and the 20D6-IM6Ab 
in the presence of sephadex-absorbed 20D8 serum, complete sets of quantita- 
tive inhibition curves were obtained.  The same  relationships  of the  various 
oligosaccharides to one another are seen in serum except that lesser amounts 
of oligosaccharides were required for comparable inhibition. In serum, the 20D,- 
IM3Ab was very readily inhibited with IM3  and  IM2  (Text-fig. 2C),  while 
the comparable amounts of oligosaccharides the IM6Ab was only poorly in- 
hibited with IM3 and was not inhibited with IM2 in the range tested (Text- 
fig.  2D).  With  the  IM3Ab,  IM5  and  IM6  gave  identical  inhibition  curves 
(Text-fig. 2C),  while with  the  IM6Ab,  IM6 was  definitely superior to IM5 
(Text-fig. 2D).  In serum also at 50 per cent inhibition point, IM3 and IM4 STUART  F.  SCHLOSSMAN  AND  ELVIN  A.  KABAT  543 
were much more effective relative to IM5 and IM6 (Text-fig. 2C) in inhibiting 
precipitation of the IM3Ab than they were in inhibiting precipitation of the 
IM6Ab (Text-fig 2D). 
Similar  results  were  obtained  with  the  antibody  fractions  of  antiserum 
1D~_~ assayed in normal human serum to the extent that data  were obtained 
(Text-fig. 1, points with asterisks). 
A point was chosen at which IM6 produced 30 per cent inhibition with  the 
20D3-IM3Ab  and dextran N  150  N; to this human  gamma globulin  Fr.  II, 
human serum albumin, and polyvinylpyrrolidone were added to test their effect 
on inhibition. It is shown in Table II that as little as 1.6 #g gamma globulin N or 
6.4 #g albumin N  will increase inhibition from 30 to 82 and 69 per  cent, re- 
spectively. That this effect is not limited to serum proteins can be seen with 
TABLE II 
The Effect of Human Gamma Globulin, Human Serum Albumin,  and Polyvinylpyrrolidone 
on Inhibition  and Precipitation with Purified Antibody 
20Ds-IM3Ab plus N  150 N 
?er cent inhibition with 
IM6 
~icrograms antibody N 
precipitated 
Saline 
30 
3.7 
Plus 
human gamma 
globulin Fr. II 
$0pg N  8pgN  1.6pgN 
86  82 
2.0  2.6  2.9 
Plus 
human serum 
albnmln 
320 pg N  32 ~g N  6.4 pg N 
90  95  69 
i 
2.9 i  2.5  3.5 
! 
Plus 
polyvinyl- 
pyrrolidone 
3.5 mgm  350 pg 
85  33 
2.1  2.5 
polyvinylpyrrolidone, as 3.5 mg will increase inhibition from 30 to 85 per cent. 
Polyvinylpyrrolidone was  less effective since 350 #g produced no significant 
inhibition.  It should be noted that the addition of these substances reduced 
the amount of antibody N  precipitated by the dextran added.  This did not 
appear to be directly related to the effect on inhibition since the increased in- 
hibiting effect was noted in instances in which no reduction in antibody N  in 
the absence of inhibitor was found and also since no increase in inhibiting effect 
was seen when the antibody N  level in the PVP was not affected (last column 
of Table II). The augmentation of inhibition in the presence of serum occurred 
with both antibody fractions from 20D3 in which addition of serum reduced 
the Ab N precipitable as well as in 1D~  fractions in which serum did not have 
this effect. 
Precipitin Studies  on the Purified Antibody Fractions with NRC Dextrans of 
Graded  Molecular  Weight.--The  behavior  of  the  unfractionated  antiserum 
20D3 with NRC dextrans of graded molecular weight is given in Text-fig. 3A. 
With this antiserum, NRC  Fr.  1, molecular weight 10,600,  precipitated con- 544  SPECIFIC  ]FRACTIONATION 0]~  ANTIDEXTRAN  MOLECULES 
siderably less antibody N  than did any of the higher molecular weight dextrans 
(of.  7).  To  determine  whether  this  difference  in  the  quantitative  precipitin 
curves  might  be  related  to  the  antibody  fractions  obtained,  the  IM3Ab  and 
IM6Ab from 20108 antiserum were set up with NRC fractions 1, 2 and 7. Text- 
fig. 3B shows that NRC Fr. 1 still precipitates less antibody N  with the IM3Ab 
than  do NRC  Frs.  2  and  7,  a  relationship  similar  to  that  in unfractionated 
serum. In Text-fig. 3C with the IM6Ab, it is seen that NRC  Fr. 1 precipitates 
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TEXT-FIt;. 3.  Quantitative precipitin curves of NRC dextran fractions of graded molecular 
weight  with 20D3  unfractionated  antidextran  serum,  purified  antibody  fractions  obtained 
from 20Da  serum, and purified antibody fractions  in the presence  of serum. 
almost as much antibody N  as do NRC Frs. 2 and 7. Figs. 3D and 3E give quan- 
titative precipitin curves of the purified antibody with the NRC  fractions  to 
which 20D3 sephadex-absorbed  serum had been added; the difference between 
Fr.  1 and Fr. 7 was greater with the IM3Ab  than with the IM6Ab. 
With the addition of serum to the purified antibody,  the shapes of the pre- 
cipitin curves are changed somewhat in that they tend to be more readily in- 
hibited in antigen excess with the lower molecular weight NRC dextrans. This 
probably accounts for the differences in Ab N  precipitated in serum and other 
proteins and in PVP when a given amount of dextran N  150 N, calculated  to 
be at the maximum for the inhibition assays with purified antibody, was used 
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Quantitative Inhibition Curves of Unfractionaled Antisera  Taken 7 to 10 Years 
Apart.--Previous  workers  have  demonstrated  that  antipolysaccharide  anti- 
bodies in man remain at or near their maximum titer for many months follow- 
ing immunization,  and then gradually decline  over a period  of years (20,  10, 
cf. 1). It was of great interest to determine whether or not the  decline  of the 
antibody level over a long period was accompanied by changes in the inhibition 
curves with oligosaccharides.  Previous studies with antidextran  (6) had  shown 
no changes over a  three year period. 
Text-fig.  4 shows quantitative inhibition  curves with  the isomaltose series 
of oligosaccharides  for two samples of antidextran  serum taken 7 to 10 years 
apart from each of two individuals and at a time when the antibody levels had 
dropped to one-third of their peak values. Serum sample 1D1~, taken in Sep- 
tember, 1954 (Text-fig.  4A) is compared with 1D~_~ taken in September, 1961 
(Text-fig.  4B), and  20D3 (February,  1952) (Text-fig.  4C)  is compared with 
20Dll (January,  1962) (Text-fig.  4D). Differences in the inhibition curves are 
minimal,  the ratios of inhibiting power of the various oligosaccharides  being 
almost the same.  IM3 gave somewhat more inhibition with 20Dn than with 
20D3. 
Immunodectrophoretic and Agar Diffusion Studies.--Fig. 1A, B, and C dem- 
onstrate that samples of 20D3-IM3Ab,  20Ds-IM6Ab as well as 20D9 enzyme 
purified  antidextran  (11),  a  preparation  containing  the entire  population  of 
antidextran  molecules,  all  migrate as fast gamma globulins when antisera  of 
different specificity were used to develop the immunoelectrophoretic patterns. 
Fig. 1D shows the same behavior with 1D~_2~-IM2Ab and 1D~4-25-IM6Ab with 
the horse anti-human serum 223-224. 
The immunoelectrophoretic patterns of the 20Da antiserum (bled February 
25, 1952), and 20Dx serum (bled October 18, 1951), a preimmunization bleed- 
ing from subject 20,  on storage in  the refrigerator for about 10 years using 
rabbit anti--T-globulin  serum pool 59 and horse anti-human  serum  223-224 
in the troughs, are seen in Figs.  1E and 1F, respectively. Wells 1 and 2 contain 
20Ds and 20D~ serum, respectively; both show a splitting of the gamma globulin 
into a fast and slow component which is not seen with the fresh 20DlI serum 
(bled January 18, 1962) in well 3, which only gives a single gamma line (experi- 
ment run on April 26,  1962). Despite the other changes which have  occurred 
in the a- and/3-globulins  (Fig.  iF) as well as in the T-globulin  (Figs.  1E and 
1F), there has been no change in the amount of antibody N  precipitable with 
dextran in the 20D8 serum over a period of 10 years, nor is there any evidence 
that  this  splitting  of the '),-globulin  involves the purified antibody fractions 
obtained from the 20D~ serum (Figs.  1A, B, and C) or the whole purified anti- 
dextran prepared with dextranase and stored in 0.01 ~ glycine for 6 years (Figs. 
1E and F, well 4). 
Fig. 2A shows that the 20Ds-IM3Ab, 20Ds-IM6Ab, gamma globulin Fr. II 
and  the 20D9 dextranase purified antibody containing  the entire population 0  0  0  0 
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of antidextran molecules,  tested in agar diffusion with horse anti-human serum 
223-224 in the center well, give bands which fuse completely. Well 5 contains 
whole serum, and demonstrates further the purity of these preparations since 
they give only a single line.  Previous data from this laboratory have demon- 
strated the antibody in the 20D3 serum to be entirely 7S in the ultracentrifuge 
(11), and in view of the recent implications that the flzA-globulins may possess 
antibody activity, Fig. 2B shows the reactions of a sheep antiserum to a fi2A- 
myeloma protein with the purified antibody fractions, "y-globulin Fr. l-I, with 
20Dn serum and with serum B1 known to contain a  large quantity of ~2A- 
globulin.  It is apparent from Fig. 2B that the purified antibody fractions are 
not fl2A-globulins, and the weak inside bands seen in wells 1 and 6 are due to 
a small amount of anti-gamma globulin present in the sheep anti-fl~-myeloma 
serum as found by immunoelectrophoresis. Fig. 2C shows complete fusion be- 
tween the various purified antibody fractions and gamma globulin Fr. II using 
rabbit anti-gamma globulin.  This antiserum shows two bands with the 20D3- 
IM3Ab fraction,  20Ds-IM6Ab fraction,  and  the  20D9 antibody which  fuse 
with one another and with gamma globulin Fr. II completely and without spur 
formation as has been previously reported (13, 21, 22) with anfisera to gamma 
globulin.  These bands are probably related to the second small gamma globulin 
line seen on immunoelectrophoresis in Figs.  1B and 1C, since some antisera to 
gamma globulin give two bands on immunoelectrophoresis (23-25). 
DISCUSSION 
Previous studies (6, 5, 26) have shown that the antidextran antibodies pro- 
duced by different individuals  in  response  to dextran  give inhibition  curves 
under comparable conditions of assay in which the relative inhibiting  power 
of IM2, IM3, IM4, and IM5 to that of IM6 and IM7 is not constant, but varies 
from one person to another. This has been interpreted as indicating that each 
individual formed a heterogeneous population of antibody molecules with com- 
bining sites of various sizes,  with the upper limit being that  complementary 
to a hexa- or heptasaccharide,  but with the proportion of antibody molecules 
with combining sites of any given size varying from individual  to individual. 
The lower limit for the size of an  antidextran  combining site has not been es- 
tablished. 
A crucial test of the validity of this hypothesis  would be the fractionation 
of antidextran from a single individual into  two populations of antibody mole- 
cules and the demonstration that these two populations differed in the ratios of 
inhibiting power of the various isomaltose oligosaccharides  as compared with 
IM6 and  IMT.  The studies reported  above have established this and hence 
provide substantial support for the hypothesis. 
It was shown that the antidextran in serum 1D~.2~ and 20D3 could each be 
fractionated  into  two portions  of  antibody of  comparable  purity,  one,  the 548  SPECIFIC  ]~RACTIONATION  O]F  ANTIDEXTRAN  MOLECULES 
1D~_~-IM2Ab or 20Ds-IM3Ab  consisting  largely of antibody molecules with 
smaller size combining  sites, and the second, the 1D2,.25-IM6Ab or the  20D~ 
IM6Ab being made up of molecules with larger  size combining  sites  as evi- 
denced by the differences in the inhibition curves shown in Text-figs.  1 and 2. 
Both the  1D~_~-IM2Ab and  the 20D3-IM3Ab, with predominantly smaller 
size combining  sites  still  contain antibody with larger  combining  sites  since 
IM7, IM6, IM5 and IM4 were better inhibitors on a molar basis  than were 
IM2 and IM3,  thus indicating the incompleteness  of  the fractionation pro- 
cedure.  Despite such incomplete  fractionation, these antibody solutions  differ 
strikingly from those with the larger combining sites. Indeed, the 20D3-IM3Ab 
fraction was maximally inhibited by IM5, IM6, and IM7 on a molar basis in- 
dicating that antibody molecules with combining sites larger than a pentasac- 
charide are not present in detectable amounts. With the 20Ds-IM6Ab  (Fig. 
2B), IM7 is the best inhibitor and is significantly better than I]~[6, indicating 
that antibodies with combining sites complementary to a hexa- and heptasac- 
charide have been concentrated in this fraction, and suggesting that the original 
serum contained a  small proportion of antibodies with combining  sites  com- 
plementary to a heptasaccharide which could at best barely be detected (Text- 
fig. 4C).  The proportion  of antibody molecules  with combining  sites  large 
enough to accommodate a chain of 7 glucoses in a-1,6 linkage cannot be in- 
ferred from these data. It would not be surprising if a small percentage of anti- 
body molecules have combining sites larger than that of 7 glucoses. Ultimately, 
further fractionation of antibody to obtain more uniform populations might 
make it possible to establish  both the lower and upper  limits for combining 
site size. 
While a given degree of inhibition with the purified antibody solutions  re- 
quired much more of an oligosaccharide  than was needed using  the original 
serum,  the inhibition curves obtained (Text-figs. 2C and 2D)  when the anti- 
bodies were reconstituted in normal serum show that the differences between 
IM3Ab and the IM6Ab were maintained and that the fractionation of the 
antibody into two populations with different proportions of combining sites of 
various sizes could be demonstrated equally well in serum. 
The basis for the difference in the quantity of oligosaccharide required  for 
a given degree of inhibition in serum as compared with that using purified anti- 
body is not known, but the effects of serum could be reproduced  with normal 
human gamma globulin, human serum albumin or even polyvinylpyrrolidone 
(Table II). The effect is definite but is somewhat obscured by the finding that 
somewhat less antibody N is sometimes precipitated by antigen when a given 
amount of antibody N is added to normal serum or to these other media. 
The immunoelectrophoretic  and agar diffusion studies (Figs. 1 and 2) clearly 
establish  that all of the antidextran produced is gamma globulin, good reac- 
tions being evident with anti-gamma globulin with complete fusion of bands STUART  ~P.  SCHLOSSMAN  AND  ELVIN  A.  KABAT  549 
between the antibody fractions and gamma globulin Fr. II. Evidence that the 
purified antibody was not a/~2A-globulin was obtained with an anti-fl,A-mye- 
loma globulin; no reaction was obtained with other antibodies present in horse 
antihuman serum. All of the antidextran produced by subject 20 had a  sedi- 
mentation constant in the ultracentrifuge of 7S  (11).  The antibody fractions 
both  showed  the  same mobility in  immtmoelectrophoresis, corresponding to 
that of fast gamma globulin, and the 20D3 antibody fractions had the same 
mobility as did an antibody obtained from an antiserum to dextran by diges- 
tion of the dextran-antidextran specific precipitate with dextranase; this solu- 
tion contained all of the antidextran originally present in the antiserum. Thus 
all of the differences between the two antibody fractions obtained by this spe- 
cific sequential elution with oligosaccharides of increasing size appears to be 
ascribable to differences in the area of their specific antibody-combining sites. 
The quantitative precipitin curves with the NRC dextran fractions of graded 
molecular weight (Text-fig. 3) show that the fractionation of the antibody es- 
tablished by inhibition curves was accompanied by a fractionation with respect 
to quantitative precipitating capacity of the NRC fractions relative to one 
another. Thus fraction 1 precipitated Jess antibody from the 20D3-IM3Ab than 
it did from the 20D3-IM6Ab relative to that precipitated by  NRC dextrans 
6 and 7; this was also true when the assays were carried out in whole serum, 
although the curves were somewhat changed in shape. The significance of these 
findings is difficult to evaluate, but it at least raises the possibility that the low 
molecular weight NRC  fraction  1  may be  preferentially precipitating anti- 
dextran with the larger size combining sites and that ultimately these differences 
in precipitating power will prove to be interpretable in terms of reactivity with 
antibodies of varying size combining sites. Quantitative precipitin curves with 
more highly fractionated and more homogeneous antibody will be of substantial 
importance. 
An individual once immunized to dextran continues to make antibody for 
as long as 10 years with only a  slow decline in titer (10,  20, cf.  reference 1), 
but continues to manufacture more or less the same heterogeneous population 
of antibodies with only minimal changes being detectable over  this period. 
It is incumbent on proponents of any theory of antibody formation to take 
these data into account as well as to explain the remarkable differences in the 
response of man to carbohydrate and protein antigens. 
SUMMARY 
Two human antidextran sera were each fractionated into two populations of 
antibody by specific  absorption  of the  anfidextran on an insoluble dextran 
(sephadex),  washing away non-specific protein,  eluting the  first fraction  of 
antibody with isomaltose or isomaltotriose, and the second fraction with iso- 
maltohexaose. The differences in behavior of the purified antibody fractions 550  SPECIFIC  ~RACTIO~ATION  OF  ANTIDF, XTRAN  ~OL~-CI~-~S 
alone, or reconstituted in serum, in quantitative inhibition studies with the 
isomaltose series  of oligosaccharides, or in quantitative precipitin studies with 
NRC dextrans of graded molecular weight, could be ascribed to differences in 
the sizes  of their combining sites.  It was shown that the antibody fractions 
eluted with isomaltose or isomaltotriose were made up largely of antibodies 
inhibited readily by the smaller oligosaccharides and therefore having a higher 
proportion of molecules with smaller-sized combining sites; whereas those frac- 
tions eluted with isomaltohexaose contained primarily antibodies readily in- 
hibitable only with the larger oligosaccharides, and hence were considered to 
have a higher proportion of larger-sized combining sites. The purified antibody 
fractions were shown to be only fast gamma globulin,--to possess the same mo- 
bility  in  immunoelectrophoresis; in  addition  the  antibody  fractions  from 
one individual in double diffusion in agar  gave lines which fused with  one 
another, with gamma globulin Ft. II, and with a purified antidextraa solution 
containing the entire population of antidextran antibodies. Evidence was also 
presented which indicated little or no change in the populations of antibody 
molecules produced in these two individuals for a period as long as 10 years 
following immunization. It is felt that these data offer substantial support for 
the hypothesis that the antidextran produced in a  single individual consists 
of a heterogeneous population of antibody molecules with antibody-combining 
sites of various sizes. 
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EXPLANATION OF PLATES 
PLATE 74 
Fxo.  1.  A.  Comparison  of immunoelectrophoretic  patterns  of  (i)  20D3-IM3Ab, 
(2) 20Ds-IM6Ab,  (3)  20Du serum, (4)  20D9 enzyme purified  antibody; horse anti- 
human serum  223-224 was used in the troughs to develop reactions (16). B. Same 
as A  except that troughs contain rabbit anti-gamma globulin  serum  pool 59 (12). 
C.  Same  as  A  except that  troughs  contain rabbit  anti-specific  precipitate serum 
134~.5 (13). D. Comparison of immunoelectrophoretic  patterns of (I) ID~.~-IM2Ab 
(2)  1D~.2s serum,  and  (3)  1D~4.~-IM6Ab using  horse anti-human  serum  223-224 
E. Comparison of immunoelectrophoretic  patterns of serum of old and recent bleed- 
ings from the same individual:  (1) 20D8 (bled February 26,  1952), (2)  20Dx (pre- 
immunization)  (bled  October 8,  1951), (3)  20Dn (bled January  18,  1962) and  (4) 
20D~ enzyme purified  antibody  (prepared  September 7,  1956 from serum  drawn 
September 24, 1954) using rabbit anti-gamma globulin pool 59. F. Same as E, except 
troughs contain horse anti-human serum  223-224. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 116  PLATE  74 
(Schlossman and  Kabat:  Specific  fractionation of antidextran molecules) PLATE 75 
FIG.  2.  A.  Center  well:  horse  anti-human  serum  223-224.  Peripheral  wells,  (1) 
20Ds-IM3Ab, (2) human gamma globulin, Fr. II, (3) 2ODs-IM6Ab, (4) 20D9 enzyme 
purified antibody, (5)  20Dn serum 1/3 dilution and  (6) empty. B. Center well: sheep 
anti-C/2A-myeloma globulin.  Peripheral wells,  (1)  to  (5)  same as in A,  (6)  serum BI 
1/3  dilution,  known  to contain a  high level of /32A-globulin.  C.  Center wells: rabbit 
anti-gamma globulin  pool 59.  Peripheral  wells  (1)  and  (6)  20D~-IM3Ab,  (2)  20D~- 
IM6Ab,  (3)  and  (4)  gamma globulin, Fr.II, and  (5)  23D9 enzyme-purified antibody. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  116  PLATE  1,3 
(Schlossman  and  Kabat:  Specific fractionation  of antidextran  molecules) 